April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
The IL-10 -1082 SNP and IL-10 and PDCD4 Expression in CNS and Retinal Lymphoma
Author Affiliations & Notes
  • H. L. Ramkumar
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland
    Howard Hughes Medical Institute, Chevy Chase, Maryland
  • D. Shen
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland
  • J. Tuo
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland
  • J. R. Smith
    Casey Eye Inst Biomed Res Bldg, Oregon Health Sciences Univ, Portland, Oregon
  • S. E. Coupland
    Cellular & Molecular Pathology, University of Liverpool, Liverpool, United Kingdom
  • C.-C. Chan
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland
  • Footnotes
    Commercial Relationships  H.L. Ramkumar, None; D. Shen, None; J. Tuo, None; J.R. Smith, None; S.E. Coupland, None; C.-C. Chan, None.
  • Footnotes
    Support  NEI Intramural Research Program, Howard Hughes Medical Institute
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4278. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. L. Ramkumar, D. Shen, J. Tuo, J. R. Smith, S. E. Coupland, C.-C. Chan; The IL-10 -1082 SNP and IL-10 and PDCD4 Expression in CNS and Retinal Lymphoma. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4278.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Most CNS and retinal B-cell lymphomas produce a high level of interleukin (IL)-10, which has been linked to rapid disease progression and relatively poor prognosis amongst non-Hodgkin lymphoma patients. The IL-10-1082 G allele is associated with improved survival in patients with certain systemic lymphomas. PDCD4 is a tumor suppressor gene and upstream regulator of IL-10. This study examined the correlation between IL-10 SNP, PDCD4 mRNA expression, and IL-10 expression (at transcript and protein levels) in the lymphoma cells.

Methods: : Archived paraffin-embedded sections of 37 CNS lymphomas with and without retinal lymphoma were obtained. Lymphoma cells were microdissected, and SNP typing was performed on genomic DNA. Expression of IL-10 and PDCD4 mRNA was analyzed by PCR with P32 labeled primer followed by gel separation. Lymphoma cells were microdissected from another 26 cytospin slides of retinal lymphomas, and SNP-typed for IL-10-1082. Vitreous IL-10 and IL-6 levels from these 26 patients were measured. The Wilcoxon signed rank sum test was used for statistical comparison.

Results: : Six CNS tumors carrying IL-10-1082 GG had a mean IL-10 mRNA fold level of 0.002, whereas 29 cases carrying IL-10-1082 AG and IL-10-1082 AA had a mean IL-10 mRNA fold level of 9.2 (p<0.05). The vitreous IL-10 (pg/ml) was 724±593 in IL-10-1082 GG patients (n=3) and 1794±603 in IL-10 -1082 AG and IL-10-1082 AA patients (n=21) (p<0.05). The vitreous IL-10/IL-6 ratio was 6.4±2.6 (n=3) in patients with IL-10-1082 GG and 23.5±7.1 (n=21) in patients with IL-10 -1082 AG and IL-10-1082 AA (p<0.05). CNSL patients with IL-10-1082 GG (n=6) had lower PDCD4 expression in their tumor tissue than patients (n=31) with IL-10-1082 AG and IL-10-1082 AA genotypes (p<0.05). No correlation was found between IL-10 and PDCD4 expression levels in 37 CNSL samples.

Conclusions: : In CNSL, presence of at least one IL-10-1082A allele results in higher IL-10 mRNA expression in tumor cells. Retinal lymphoma patients with at least one copy of this SNP have a higher vitreal IL-10 level and IL-10/IL-6 ratio. CNSL patients with at least one IL-10-1082 A allele have higher PDCD4 levels, but this may be independent of IL-10 mRNA expression.

Keywords: tumors • cytokines/chemokines • gene/expression 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×